麻豆社

Drug manufacturer Roche tells Dominic Laurie it will appeal a decision by the National Institute for Health and Care Excellence that a pioneering new breast cancer drug is not affordable for the NHS. The drug Kadcyla adds, on average, six months to the life of those suffering from an aggressive form of the disease. Estimates show it will cost about 拢90,000 per patient. Plus, we look at the prospects for US military intervention in Iraq as air strikes start in the north of the country.